DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA561161
Title:
A Novel Anti-Beta2-Microglobulin Antibody Inhibition of Androgen Receptor Expression, Survival, and Progression in Prostate Cancer Cells
Descriptive Note:
Final rept. 1 May 2008-2 Dec 2011
Corporate Author:
CEDARS-SINAI MEDICAL CENTER LOS ANGELES CA
Report Date:
2012-01-01
Pagination or Media Count:
31.0
Abstract:
Beta 2-microglobulin 2M is a signaling and growth-promoting factor stimulating prostate cancer cell proliferation and progression. Blockade of the Beta 2M signaling axis resulted in the inhibition of androgen receptor AR and its target gene, prostate-specific antigen PSA, and the induction of programmed death of prostate cancer cells in vitro and in vivo. Also, we identified a new cis-acting element, sterol regulatory element-binding protein-1 SREBP-1 binding site, within the 5 -flanking human AR promoter region and its binding transcription factor, SREBP-1, regulating AR transcription by anti- Beta 2M monoclonal antibody in prostate cancer cells. Furthermore, we revealed the novel molecular mechanism by which SREBP-1 promotes prostate cancer growth and progression. Alteration of SREBP-1 expression leads to regulate AR expression, cell growth, migration and invasion in prostate cancer cells. SREBP-1 also showed to induce fatty acid and lipid formation in prostate cancer cells through increase of fatty acid synthase expression. Additionally, SREBP-1 induced oxidative stress and NADPH oxidase 5 Nox5 expression in prostate cancer cells. In subcutaneous xenograft mouse models, SREBP-1 significantly increased LNCaP tumor growth and promoted prostate tumor castration-resistant progression. These findings provided a new concept to reveal the role of Beta 2M and its related signaling pathways, including AR, SREBP-1, fat metabolism and oxidative stress, contribute to prostate cancer growth, survival and progression, and further provides a new potential target to prevent and treat prostate cancer malignancy by using anti-Beta 2M monoclonal antibody.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
